CurrentCignaPolicy N/A

Idiopathic Pulmonary Fibrosis and Related Lung Disease - Pirfenidone Prior Authorization Policy

Defines prior authorization requirements for prescription benefit coverage of pirfenidone (Esbriet and generic) for idiopathic pulmonary fibrosis for Cigna-administered health benefit plans; applies to prescribers and coverage reviewers.

Policy Summary

PayerCigna

PolicyPirfenidone (Esbriet) prior authorization for idiopathic pulmonary fibrosis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJul 16, 2025

Key ActionObtain prior authorization; approvals are provided for one year when criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 yearapproval duration

>=18minimum age

>=40% FVCbaseline FVC threshold

Concomitant with nintedanibnot covered

Coverage Criteria for Pirfenidone (Esbriet)

FDA-Approved Indication: Idiopathic Pulmonary Fibrosis

Policy Summary

PayerCigna

PolicyPirfenidone (Esbriet) prior authorization for idiopathic pulmonary fibrosis

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJul 16, 2025

Key ActionObtain prior authorization; approvals are provided for one year when criteria are met.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Overall allowance

A) Initial Therapy
- Age: Patient is >= 18 years of age>= 18 years
- Lung function: Forced vital capacity is >= 40% of predicted>= 40% FVC
- Diagnosis confirmation
  - HRCT: Findings on high-resolution computed tomography indicate usual interstitial pneumonia
  - Biopsy: Surgical lung biopsy demonstrates usual interstitial pneumonia
- Prescriber: Medication is prescribed by or in consultation with a pulmonologist
B) Currently Receiving Pirfenidone
- Age: Patient is >= 18 years of age>= 18 years
- Response: Patient has experienced a beneficial response to therapy over the last year (if <1 year, response compared to baseline)
  Examples: reduction in anticipated decline in FVC, six-minute walk distance, or reduction in number/severity of IPF exacerbations
- Prescriber: Medication is prescribed by or in consultation with a pulmonologist

ref (! DO NOT EDIT) !must match planner id exactly: inv-01? No but spec requires ref field exactly as given. Please correct. I'm ChatGPT. Replace with proper field. Sorry. This is invalid JSON.

Medication and Clinical Coding

Covered medicationNDC | mixedCovered

Esbriet (pirfenidone) - brand/generic

Esbriet® (pirfenidone capsules and film-coated tablets - Genentech, generic) is covered as medically necessary when criteria are met for FDA-approved indications.

Baseline forced vital capacity

Baseline %FVC threshold for initial therapy>= 40% of predicted

Typical trial enrollment thresholdPhase III trials required %FVC >= 50% at baseline

Evidence for lower %FVCSome information suggests patients with %FVC < 50% may also benefit

Provider Requirements and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization required — prior authorization is required for pirfenidone (Esbriet and generic); approvals typically for 1 year when criteria met. Because of the specialized skills required for evaluation and diagnosis of patients treated with pirfenidone, approval requires pirfenidone to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Approvals are generally for 1 year when criteria are met.
Prescriber requirement: prescribed by or in consultation with a pulmonologist or specialist in the condition.

Step Therapy

Step therapy — no step therapy requirements are specified in this policy. Requests will be evaluated against the medical necessity criteria; no prerequisite medications are required before initiating pirfenidone.

Documentation Required

Required Clinical and Response Documentation

Required clinical documentation — documentation must confirm patient age, baseline % predicted FVC, and diagnostic confirmation of idiopathic pulmonary fibrosis (HRCT with UIP pattern or surgical lung biopsy showing UIP). For continuation requests, documentation must demonstrate a beneficial response to therapy over the last year (or from baseline if the patient has received <1 year of therapy). Examples of beneficial response include reduced decline in FVC, improved or stabilized six-minute walk distance, or fewer/less severe IPF exacerbations.

Confirm age ≥ 18 years.
Document baseline and current % predicted forced vital capacity (FVC).
Provide HRCT or surgical lung biopsy results confirming usual interstitial pneumonia (UIP) pattern, OR documentation supporting diagnosis of IPF.
For continuation: document beneficial response over the last year (or from baseline if <1 year of therapy).

Denial Risk

Concomitant Therapy Exclusion

Concomitant therapy exclusion — pirfenidone used in combination with nintedanib (Ofev) is considered not medically necessary. Requests for concomitant use will be denied.

Concomitant use with Ofev (nintedanib) is not covered and will be denied as not medically necessary.

Billing Rule

Incorrect Coding / Unsupported Diagnosis

Incorrect coding/unsupported diagnosis — claims submitted without a covered diagnosis or without the appropriate supporting clinical documentation will be denied as not covered. Providers must bill using the most appropriate diagnosis and procedure codes as of the date of service and include documentation that aligns with the policy’s covered indications.

Claims without covered diagnosis/procedure codes or without required documentation will be denied as not covered.
Use the most appropriate and current codes for the date of service; include clinical documentation supporting the covered indication.

Definitions and Clinical Terms

Idiopathic pulmonary fibrosis (IPF)

Definition of IPFA chronic interstitial lung pneumonia with a histologic usual interstitial pneumonia (UIP) pattern or a characteristic high-resolution CT for IPF

Exclusion of other causesFindings (UIP pattern on histology or HRCT) must not be due to infection or cancer

Diagnostic confirmation methodsDiagnosis may be confirmed by HRCT showing UIP or by surgical lung biopsy demonstrating UIP

Forced vital capacity (%FVC)

%FVC term definitionPercent predicted forced vital capacity (FVC) used to assess baseline lung function and eligibility

Policy eligibility threshold>= 40% of predicted for initial therapy

Clinical trial contextPhase III trials required %FVC >= 50% at baseline; trials demonstrated reduced decline in %FVC with pirfenidone

Background

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia characterized by a usual interstitial pneumonia (UIP) pattern on histology or high-resolution CT and is associated with progressive dyspnea and impaired lung function. Pirfenidone (Esbriet) is FDA-approved for the treatment of IPF and has been shown in randomized trials to reduce the rate of decline in forced vital capacity (FVC). Prior authorization is required for pirfenidone for Cigna-administered plans; when criteria are met, approvals are provided for 1 year.